RELIEF THERAPEUTICS Holding AG

LSE 0QKQ
£2.85 0.14 4.98%
Today share price
UK
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
54.17M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
39.57M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-14.74
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
12.54M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-32.26 %

Upcoming events RELIEF THERAPEUTICS Holding AG

All events
No upcoming events scheduled

Stock chart RELIEF THERAPEUTICS Holding AG

Stock analysis RELIEF THERAPEUTICS Holding AG

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.47 14.73
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.44 -
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.32 4.29
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.12 -
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-314.48 -

Price change RELIEF THERAPEUTICS Holding AG per year

1.85£ 6.60£
Min Max

Summary analysis RELIEF THERAPEUTICS Holding AG

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure RELIEF THERAPEUTICS Holding AG

Revenue and net income RELIEF THERAPEUTICS Holding AG

All parameters

About company RELIEF THERAPEUTICS Holding AG

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
Address:
Avenue de Secheron 15, Geneva, Switzerland, 1202
Company name: RELIEF THERAPEUTICS Holding AG
Issuer ticker: 0QKQ
Country: UK
Exchange: LSE
Currency: £
Sector: Industrials
Site: https://www.relieftherapeutics.com